ArticleInternational journal of nanomedicine2026
Macrophage Membrane-Camouflaged Mesoporous Polydopamine Nanoparticles for Targeted Delivery of Apigenin in Sepsis-Induced Acute Lung Injury.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Sepsis-induced acute lung injury (ALI) is a critical illness that poses a serious threat to human health, and effective treatments remain lacking. This study aimed to develop a macrophage membrane-biomimetic nano-delivery system loaded with mesoporous polydopamine (MPDA)-encapsulated apigenin (API) and to investigate its therapeutic potential in ALI. Methods: In this study, we developed a macrophage membrane-coated biomimetic nano-delivery system, designated MEM@MPDA/API nanoparticles (NPs). We first systematically characterized the physicochemical properties of MEM@MPDA/API, and then evaluated its cellular uptake, reactive oxygen species (ROS) scavenging capacity, and mitochondrial function restoration through in vitro experiments. In vivo, after constructing an ALI mouse model, we assessed its active targeting to lung tissue, anti-inflammatory efficacy, pulmonary barrier repair capacity, and tissue safety following tail vein administration. Results: In vivo results demonstrated that MEM@MPDA/API NPs effectively scavenged ROS, reduced inflammatory cytokine levels, and restored mitochondrial function. In the ALI mouse model, these NPs efficiently accumulated in the injured lung regions, alleviated pulmonary histopathological damage, and repaired the alveolar epithelial barrier. Integrated single-cell transcriptomics analysis and network pharmacology studies revealed that mitophagy-related pathways were activated during the progression of ALI. Conclusion: This study proposes a promising biomimetic nano-delivery strategy, providing a safe and efficient potential new approach for the application of biomimetic nanomedicine in the treatment of ALI and oxidative stress-related critical diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.